vs

Side-by-side financial comparison of BKV Corp (BKV) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $255.9M, roughly 1.3× BKV Corp). BKV Corp runs the higher net margin — 27.5% vs -18.2%, a 45.7% gap on every dollar of revenue.

BKV Corp is a North American independent energy company focused on sustainable natural gas exploration, production, and distribution, with core operating assets located in the Appalachian Basin. It serves utility, industrial, and commercial customers across the region, and invests in low-carbon technologies including carbon capture to reduce operational emissions.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

BKV vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.3× larger
MDGL
$321.1M
$255.9M
BKV
Higher net margin
BKV
BKV
45.7% more per $
BKV
27.5%
-18.2%
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BKV
BKV
MDGL
MDGL
Revenue
$255.9M
$321.1M
Net Profit
$70.4M
$-58.6M
Gross Margin
Operating Margin
39.3%
-18.6%
Net Margin
27.5%
-18.2%
Revenue YoY
210.8%
Net Profit YoY
1.4%
EPS (diluted)
$0.78
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BKV
BKV
MDGL
MDGL
Q4 25
$255.9M
$321.1M
Q3 25
$199.8M
$287.3M
Q2 25
$207.1M
$212.8M
Q1 25
$231.0M
$137.3M
Q4 24
$103.3M
Q3 24
$133.5M
$62.2M
Q1 24
$0
Q4 23
$0
Net Profit
BKV
BKV
MDGL
MDGL
Q4 25
$70.4M
$-58.6M
Q3 25
$76.8M
$-114.2M
Q2 25
$104.6M
$-42.3M
Q1 25
$-78.7M
$-73.2M
Q4 24
$-59.4M
Q3 24
$12.9M
$-107.0M
Q1 24
$-147.5M
Q4 23
$-112.2M
Gross Margin
BKV
BKV
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q1 24
Q4 23
Operating Margin
BKV
BKV
MDGL
MDGL
Q4 25
39.3%
-18.6%
Q3 25
41.2%
-39.7%
Q2 25
62.0%
-22.2%
Q1 25
-40.6%
-57.8%
Q4 24
-64.8%
Q3 24
-15.7%
-187.1%
Q1 24
Q4 23
Net Margin
BKV
BKV
MDGL
MDGL
Q4 25
27.5%
-18.2%
Q3 25
38.5%
-39.8%
Q2 25
50.5%
-19.9%
Q1 25
-34.1%
-53.4%
Q4 24
-57.5%
Q3 24
9.6%
-172.0%
Q1 24
Q4 23
EPS (diluted)
BKV
BKV
MDGL
MDGL
Q4 25
$0.78
$-2.55
Q3 25
$0.90
$-5.08
Q2 25
$1.23
$-1.90
Q1 25
$-0.93
$-3.32
Q4 24
$-2.50
Q3 24
$0.18
$-4.92
Q1 24
$-7.38
Q4 23
$-5.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BKV
BKV
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$199.4M
$198.7M
Total DebtLower is stronger
$486.8M
$339.9M
Stockholders' EquityBook value
$2.0B
$602.7M
Total Assets
$3.1B
$1.3B
Debt / EquityLower = less leverage
0.24×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BKV
BKV
MDGL
MDGL
Q4 25
$199.4M
$198.7M
Q3 25
$83.1M
$295.7M
Q2 25
$21.4M
$186.2M
Q1 25
$15.3M
$183.6M
Q4 24
$100.0M
Q3 24
$31.3M
$232.7M
Q1 24
$622.5M
Q4 23
$99.9M
Total Debt
BKV
BKV
MDGL
MDGL
Q4 25
$486.8M
$339.9M
Q3 25
$486.6M
$339.8M
Q2 25
$200.0M
$118.4M
Q1 25
$200.0M
$118.0M
Q4 24
$117.6M
Q3 24
$190.0M
$117.1M
Q1 24
$116.1M
Q4 23
$115.5M
Stockholders' Equity
BKV
BKV
MDGL
MDGL
Q4 25
$2.0B
$602.7M
Q3 25
$1.8B
$625.7M
Q2 25
$1.6B
$696.0M
Q1 25
$1.5B
$710.6M
Q4 24
$754.4M
Q3 24
$1.6B
$777.2M
Q1 24
$850.8M
Q4 23
$405.3M
Total Assets
BKV
BKV
MDGL
MDGL
Q4 25
$3.1B
$1.3B
Q3 25
$2.9B
$1.4B
Q2 25
$2.3B
$1.0B
Q1 25
$2.3B
$996.6M
Q4 24
$1.0B
Q3 24
$2.3B
$1.1B
Q1 24
$1.1B
Q4 23
$640.5M
Debt / Equity
BKV
BKV
MDGL
MDGL
Q4 25
0.24×
0.56×
Q3 25
0.27×
0.54×
Q2 25
0.13×
0.17×
Q1 25
0.13×
0.17×
Q4 24
0.16×
Q3 24
0.12×
0.15×
Q1 24
0.14×
Q4 23
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BKV
BKV
MDGL
MDGL
Operating Cash FlowLast quarter
$69.4M
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
0.99×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BKV
BKV
MDGL
MDGL
Q4 25
$69.4M
$-133.5M
Q3 25
$74.5M
$79.8M
Q2 25
$76.2M
$-47.1M
Q1 25
$22.6M
$-88.9M
Q4 24
$-104.5M
Q3 24
$-67.0M
Q1 24
$-149.2M
Q4 23
$-79.9M
Free Cash Flow
BKV
BKV
MDGL
MDGL
Q4 25
$-133.8M
Q3 25
$-126.9M
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q1 24
$-149.5M
Q4 23
$-81.0M
FCF Margin
BKV
BKV
MDGL
MDGL
Q4 25
-41.7%
Q3 25
-63.5%
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q1 24
Q4 23
Capex Intensity
BKV
BKV
MDGL
MDGL
Q4 25
0.1%
Q3 25
100.9%
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q1 24
Q4 23
Cash Conversion
BKV
BKV
MDGL
MDGL
Q4 25
0.99×
Q3 25
0.97×
Q2 25
0.73×
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BKV
BKV

Natural Gas NGL And Oil$249.3M97%
Related Party And Other$4.7M2%
Marketing$2.8M1%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons